Sophia Paspal, Ph.D., RAC

Sophia Paspal, Ph.D., RAC has extensive work experience in the field of regulatory affairs and quality assurance. Sophia is currently the Chief Development Officer and Executive VP Quality at Xynomic Pharma since 2019. Prior to this, they held the role of Chief Development Officer at the same company from an undisclosed date in 2019 until December 2021.

Before joining Xynomic Pharma, Sophia worked as the Vice President of Regulatory Affairs and Quality Assurance at Capricor Therapeutics, Inc. from September 2018 to an undisclosed date in 2019. Prior to this, they held a similar position at Cellics Therapeutics, Inc. from an undisclosed date in 2017 until September 2018.

Sophia has also held positions at prominent pharmaceutical companies such as Halozyme Therapeutics, Inc., Dart NeuroScience LLC, Shire Pharmaceuticals, Allergan, Pfizer (Legacy Wyeth), Incyte Pharmaceuticals, and GlaxoSmithKline. These roles have involved regulatory affairs and quality assurance responsibilities at various levels of seniority.

Their experience spans over two decades, starting in 1999 at GlaxoSmithKline as an Investigator in Pharmaceutical Development. Throughout their career, Sophia has held positions of increasing responsibility, including Director of Regulatory Affairs, Associate Director of Regulatory Affairs, and Senior Manager of Global Regulatory Affairs.

Their diverse work experience has allowed Sophia Paspal to develop a deep understanding of regulatory requirements and quality standards in the pharmaceutical industry. Their expertise and leadership skills make their a valuable asset in the development and execution of regulatory strategies.

Sophia Paspal, Ph.D., RAC completed their education in a chronological order. Firstly, from 1993 to 1994, they obtained their Bachelor of Science degree in Chemistry from the University of Minnesota. Following this, they pursued a Ph.D. in Pharmaceutics from the same university, which they completed from 1994 to 1999 in the College of Pharmacy. Additionally, Sophia holds a certification in Regulatory Affairs, which they obtained from the Regulatory Affairs Professionals Society (RAPS) in November 2013.

It should be noted that there is no available information about their education at the University of Science and Technology of China, except the name of the institution. Moreover, they also completed a program at Temple University RA/QA, focused on Clinical and Industrial Drug Development, but the years of this program are unspecified.